World’s smallest graphene computer to cure cancer

Dr. Claude Vezeau President & CEO - Calevia

Dr. Claude Vezeau
President & CEO – Calevia

A new technology announced by ProScanRxPharma Inc., Grafoid Inc. and Calevia Inc. can selectively search and destroy cancerous prostate cells and destroy them with a flash of red light combining biotechnology and advanced graphene technologies to provide ground-breaking new medical technology.

Reaching this level of innovation requires massive mastery of several fields of science, an effort with massive commercial applications. This is about finding the Holy Grail of cancer therapy: destroying cancer cells without difficult surgery that may or may not eliminate all the cancerous cells, or death defying chemotherapy. For many years now, researchers have been looking at ways to use graphene in cancer therapy by providing a focused way to eliminate cancer cells.

The new technology is rooted in a rudimentary principle that was discovered 100,000 years ago with the discovery of fire: fire burns — and further experimented by every toddler ever since.

Subscribe here to receive free daily   InvestorIntel   updates

Next it is draws on immunology, perhaps one of most misunderstood facet of medicine, by using antibodies that are specific to cancer cells. These antibodies bind to the walls of cancer cells but are rejected by healthy cells. Antibodies are the business end of the immune system that binds to microbes and foreign substances. In carcinogenesis the immune system is unable to produce them to destroy cancer cells. But what if we could arm antibodies with heat guns?  Living cells are sensitive to high temperature — fire burns.

The researchers then used the antibodies to coat minuscule amounts of graphene, a single layer of carbon atoms, thus forming a bioconjugate or a biological computer chip. These graphene chips were fabricated for their ability to bind to the non-business end of the antibodies so that when they encounter cancer cells they can bind to their cell walls. This required finding a way to detoxify graphene, a unique process that was developed by Grafoid — graphene oxide is normally toxic to living cells.

graphene cancer treatmentThis is when things get nasty for cancer cells: when graphene is exposed to near infrared wavelength, it turns it instantly turns it into heat. Near infrared is harmless red light and can’t be felt normally:  TV remotes use near infrared waves. Near infrared can also penetrate tissues, hence it can reach tumours that are coated with the antibody-graphene bioconjugate. Again, we know that fire burns. In this case it only burns the cancerous cells.

According to Calevia’s co-founder Dr. Claude Vezeau who serves as President and CEO, further research is needed to calibrate the heat exposure to optimize the tumour removal treatment.  In parallel, further research will also add therapies for example breast, kidney, bladder, and bladder cancers. So far these findings have been demonstrated on animal trials. Clinical trials on human subjects are planned within a 2-year horizon.

If these findings can be proven to cure cancer in humans, Calevia might offer us as much a quantum leap in medicine as when Sir Alexander Fleming and co-workers developed the antibiotic substance penicillin from the fungus Penicillium notatum in 1928. Fleming took medicine to a completely new level and triggered the pharmaceutical industry as we know it today.


Copyright © 2016 InvestorIntel Corp. All rights reserved. More & Disclaimer »
This entry was posted in Biotech Intel, Technology Metals Intel and tagged , by Dr. Luc Duchesne. Bookmark the permalink.
Dr. Luc Duchesne

About Dr. Luc Duchesne

Dr. Luc C. Duchesne is a Speaker and Author with a PhD in Biochemistry. With three decades of scientific and business experience, he has published 85 scientific papers, and has recently published his first novel, "The Moose Motel: A Tale of Golden Revenge". The Founder and CEO for GSN DreamWorks Inc. based in Ottawa, Luc is a regular columnist for InvestorIntel.
  1. This is incredible! I did not really understand the impact of graphene until a friend recommended this site a few months ago. We all know people who have suffered from prostrate cancer or had to deal with it’s impact on a beloved family member so to read this hear today was well incredible! I am absolutely excited about this and am going to look seriously at this stock right now before the news is everywhere! Off to my online trading account…

  2. Like the discovery of Pennicillin 100+ years ago could this be the “Magic Bullet”.? Cancer has been the bane of humankind forever. Now at long last we have a non-invasive weapon to battle this heinous foe. Graphite / graphene combined with heat & nanotechnology could be just the beggining. We’ve heard it said for years but perhaps it’s true, Cancer can be Beaten.

    • Thank you for your email Steve. I have forwarded you inquiry to Calevia’s team and have asked that they will respond. As with all technological & medical advancements in biotech, there are rigorous processes that a company must go through before being available to the population. I am, however — a believer in fast tracking solutions…we will keep you updated as I do not know a person in my life that has not been affected by cancer, either directly or indirectly.

  3. Pingback: Graphene: making computing faster, cheaper and greener |

  4. Pingback: Creativity proves a timely laxative for capital constipation in the junior markets.

  5. Pingback: Focus Graphite -- it's all about the numbers | InvestorIntel

  6. Pingback: Offtake agreement announced; Focus Graphite makes history | InvestorIntel

    • Thank you for drawing attention to this article, as we will be having a Biotech section added to InvestorIntel in the next month and the cure for cancer is undoubtedly one of the greatest goals a company could achieve…any cancer.

  7. Pingback: Visionaries at Grafoid make sensational news; Zenyatta weathers the storm admirably | InvestorIntel

Leave a Reply

Your email address will not be published. Required fields are marked *